Oregon Health & Science University Hospital and Clinics Provider's Orders	ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE			
Page 1 of 2	Patient Identification			
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.				
Weight:kg Height: Allergies:				
Diagnosis Code:				

Treatment Start Date: _____ Patient to follow up with provider on date: ___

This plan will expire after 365 days at which time a new order will need to be placed

GUIDELINES FOR ORDERING

- 1. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with mepolizumab. Decrease corticosteroids gradually, if appropriate.
- 2. Herpes zoster infections have occurred in patients receiving mepolizumab. Consider varicella vaccination if medically appropriate prior to starting therapy with mepolizumab.
- 3. Treat patients with pre-existing helminth infections before therapy with mepolizumab. If patients become infected while receiving treatment with mepolizumab and do not respond to anti-helminth treatment, discontinue mepolizumab until parasitic infection resolves.

MEDICATIONS:

mepolizumab (NUCALA) injection, subcutaneous, ONCE.

Asthma:

□ 100 mg

Eosinophilic granulomatosis with polyangitis (treatment) Dose:

□ 300 mg (administer as THREE separate 100 mg injections at a distance 5 cm or more apart)

Interval:

□ Every 4 weeks

NURSING ORDERS:

- 1. Administer subcutaneously into the upper arm, thigh, or abdomen. Do not inject into skin that is tender, bruised, red, or hard.
- 2. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.
- 3. Observe patient for hypersensitivity reactions, including anaphylaxis, for 30 minutes after administration.

OHSU	Oregon Health & Science University Hospital and Clinics Provider's Orders ADULT AMBULATORY INFUSION ORDER Mepolizumab (NUCALA) Subcutaneous Injection	ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE	
	Page 2 of 2	Patient Identification	
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.			

HYPERSENSITIVITY MEDICATIONS:

- NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, Tuality C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
- diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x1 dose for hypersensitivity reaction
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity reaction
- 4. famotidine (PEPCID), 20 mg, intravenous, AS NEEDED x1 dose for hypersensitivity reaction
- 5. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity reaction

By signing below, I represent the following:

I am responsible for the care of the patient (who is identified at the top of this form);	
I hold an active, unrestricted license to practice medicine in: Oregon	(check box
that corresponds with state where you provide care to patient and where you are currently licens	ed. Specify
state if not Oregon);	

My physician license Number is # ______ (MUST BE COMPLETED TO BE A VALID

PRESCRIPTION; and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature:	Date/Time: _	
Printed Name:	Phone:	Fax:

Please check the appropriate box for the patient's preferred clinic location:

TUALITY HEALTHCARE An OHSU Partner

Infusion Services 364 SE 8th Ave, Medical Plaza Suite 108B Hillsboro, OR 97123 Phone number: (503) 681-4124 Fax number: (503) 681-4120



Celilo Cancer Center 1800 E 19th St The Dalles, OR 97058 Phone number: (541) 296-7585 Fax number: (541) 296-7610